Welcome to BioSeeker Group!

Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

Additional Information

Published Date May 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 2940
PDF Fact Sheet View Fact Sheet for the report Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

Regular Price: $2,950.00

Special Price: $1,475.00

Quick Overview

This report represents a new and unique way of stratifying and analyzing the global protein kinase drug pipeline in oncology towards personalized medicine.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others.

    To find out more about Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report represents a new and unique way of stratifying and analyzing the global protein kinase drug pipeline in oncology towards personalized medicine. It will excel your competitive awareness and decrease your decision making time in managing protein kinase drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

A large number of drugs, both on the market and in development have protein kinase modulating properties.This report includes both direct protein kinase targets and indirect protein kinase targets (non-protein kinase targets which nevertheless have protein kinas effects).

This report comprises defined and up to date development strategies for 648 protein kinase drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the protein kinase drug pipeline in oncology and discern the level of competition in fine detail.

Major Findings from this report:
* The identified competitive landscape of protein kinase drugs in cancer is split between the 30% which have unique drug target strategies and the other 70% which have head-to-head target competing drugs in 81 different clusters. The latter has a competing ratio which is more two times higher than the comparable average of the protein kinase drugs in general.

* Eight out of every ten drug target strategies in Phase III development are new to protein kinase drugs, whereas only less than four out of every ten target strategies in Phase I are new.

* The greatest number of new target strategies are found in Preclinical (29%) and Phase II (20%) development.

* Small molecules, Antibodies and Nucleic Acids drugs are the dominating compound strategies of protein kinase cancer drugs, which represent almost 95% of the entire pipeline.

* Protein based protein kinase cancer drugs has the highest cross-over of drug target strategies with other compound strategies, especially with that of Small Molecules and Antibodies.

* Protein kinase drugs are experiencing targeting competition in nearly seven out of every ten cancer indications described, and more so in breast-, non-small cell lung- and colorectal cancer.

* The highest number of described target strategies among protein kinase drugs are found in breast-, colorectal-, non-small cell lung-, ovarian- and prostate cancer

* Out of the 212 companies, the highest number of described drug target strategies of protein kinase drugs belongs to Pfizer, AstraZeneca, Novartis, Exelixis and Hoffmann-La Roche

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any protein kinase drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights™ 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 Additional Information 6
2.4 BioSeeker Group’s Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights’™ Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 24
4.2 List of Tables 24
5 Introduction 38
5.1 The Scope of this Report 38
5.2 Definitions 41
5.3 Abbreviations 41
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment 42
6.1 Drug Repositioning in Oncology 42
6.2 Introduction to Targets of Protein Kinase Drugs in Oncology 43
6.2.1 Antigen Binding Targets 50
6.2.2 ATPase Activity Targets 51
6.2.3 Carboxy-lyase Activity Targets 52
6.2.4 Catalytic Activity Targets 54
6.2.5 Cell Adhesion Molecule Activity Targets 59
6.2.6 Chaperone Activity Targets 61
6.2.7 Chemokine Activity Targets 64
6.2.8 Cysteine-type Peptidase Activity Targets 65
6.2.9 Cytokine Activity Targets 67
6.2.10 Cytoskeletal Protein Binding Targets 68
6.2.11 DNA Binding Targets 69
6.2.12 DNA Topoisomerase Activity Targets 70
6.2.13 Extracellular Ligand-gated Ion Channel Activity Targets 74
6.2.14 G-protein Coupled Receptor Activity Targets 76
6.2.15 Growth Factor Activity Targets 79
6.2.16 GTPase Activator Activity Targets 88
6.2.17 GTPase Activity Targets 89
6.2.18 Hydrolase Activity Targets 96
6.2.19 Ion Channel Activity Targets 98
6.2.20 Kinase Activity Targets 99
6.2.21 Kinase Binding Targets 115
6.2.22 Kinase Regulator Activity Targets 119
6.2.23 Ligase Activity Targets 124
6.2.24 Lipid Kinase Activity Targets 126
6.2.25 Lipid Phosphatase Activity Targets 142
6.2.26 Molecular Function Unknown Targets 144
6.2.27 Oxidoreductase Activity Targets 145
6.2.28 Peroxidase Activity Targets 146
6.2.29 Protease Inhibitor Activity Targets 147
6.2.30 Protein Binding Targets 148
6.2.31 Protein Serine/Threonine Kinase Activity Targets 152
6.2.32 Protein Threonine/Tyrosine Kinase Activity Targets 255
6.2.33 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets 264
6.2.34 Protein-tyrosine Kinase Activity Targets 266
6.2.35 Receptor Activity Targets 297
6.2.36 Receptor Binding Targets 301
6.2.37 Receptor Signaling Complex Scaffold Activity Targets 305
6.2.38 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 308
6.2.39 Structural Constituent of Cytoskeleton Targets 311
6.2.40 Structural Molecule Activity Targets 312
6.2.41 Transcription Factor Activity Targets 313
6.2.42 Transcription Regulator Activity Targets 334
6.2.43 Translation Regulator Activity Targets 339
6.2.44 Transmembrane Receptor Activity Targets 341
6.2.45 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 342
6.2.46 Transporter Activity Targets 425
6.3 The Cancer Genome Project and Targets of Protein Kinase Drugs in Oncology 429
6.3.1 Targets of Protein Kinase Drugs in Oncology Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 429
6.4 Protein Kinase Therapeutics is Stimulated by Available Structure Data on Targets 435
6.5 Target-Target Interactions among Identified Targets of Protein Kinase Drugs in Oncology 439
6.6 The Drug-Target Competitive Landscape 443
6.7 Protein Expression Levels of Identified Targets of Protein Kinase Drugs in Oncology 448
6.8 Pathway Assessment of Protein Kinase Drugs in Oncology 451
6.8.1 Tools for Analysis of Cancer Pathways 452
6.8.2 Pathway Assessment 453
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development 517
7.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Protein Kinase Drugs in Oncology 520
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Protein Kinase Drugs in Oncology 522
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Protein Kinase Drugs in Oncology 526
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Protein Kinase Drugs in Oncology 536
7.5 Preclinical Development: New and Unique Drug Target Strategies of Protein Kinase Drugs in Oncology 550
7.6 Drug Target Strategies of No Data, Suspended or Terminated Protein Kinase Drugs in Oncology 566
7.7 Target Strategy Development Profiles of Protein Kinase Drugs in Oncology 573
7.7.1 Marketed 579
7.7.2 Pre-registration 608
7.7.3 Phase III 610
7.7.4 Phase II 653
7.7.5 Phase I 733
7.7.6 Preclinical 785
7.7.7 Suspended 866
7.7.8 Ceased 868
7.8 The Competition Through Close Mechanistic Approximation of Protein Kinase Drugs in Oncology 925
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy 946
8.1 Small Molecules 948
8.1.1 Background 948
8.1.2 Target Strategies of Small Molecule Drugs 949
8.2 Peptide & Protein Drugs 987
8.2.1 Background 987
8.2.2 Target Strategies of Peptide and Protein Drugs 988
8.3 Antibodies 993
8.3.1 Background 993
8.3.2 Target Strategies of Antibody Drugs 993
8.4 Nucleic Acid Therapies 997
8.4.1 Background 997
8.4.2 Target Strategies of Nucleic Acid Drugs 998
8.5 Cell & Gene Therapy 1000
8.5.1 Background 1000
8.5.2 Target Strategies of Cell & Gene Therapy Drugs 1001
8.6 Drug Delivery and Nanotechnology 1004
8.6.1 Background 1004
8.6.2 Target Strategies of Reformulated Drugs 1004
8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 1006
9 Selecting Indication for Protein Kinase Drugs in Oncology 1014
9.1 Acute Lymphocytic Leukemia 1017
9.2 Acute Myelogenous Leukemia 1020
9.3 Adrenal Cancer 1025
9.4 B-cell Lymphoma 1026
9.5 Basal Cell Cancer 1028
9.6 Biliary Cancer 1029
9.7 Bladder Cancer 1030
9.8 Bone Cancer 1033
9.9 Brain Cancer 1034
9.10 Breast Cancer 1039
9.11 Cancer (general) 1049
9.12 Carcinoid 1051
9.13 Cervical Cancer 1053
9.14 Cervical Dysplasia 1055
9.15 Chronic Lymphocytic Leukemia 1056
9.16 Chronic Myelogenous Leukemia 1061
9.17 Chronic Myelomonocytic Leukemia 1065
9.18 CNS Cancer 1065
9.19 Colorectal Cancer 1066
9.20 Cowden syndrome 1074
9.21 Endometrial Cancer 1075
9.22 Fallopian Tube Cancer 1078
9.23 Fibro Sarcoma 1080
9.24 Gastrointestinal Cancer (general) 1081
9.25 Gastrointestinal Stomach Cancer 1084
9.26 Gastrointestinal Stromal Cancer 1088
9.27 Head and Neck Cancer 1091
9.28 Hematological Cancer (general) 1096
9.29 Hodgkin’s Lymphoma 1099
9.30 Leiomyo Sarcoma 1100
9.31 Leukemia (general) 1101
9.32 Lipo Sarcoma 1102
9.33 Liver Cancer 1103
9.34 Lung Cancer (general) 1108
9.35 Lymphangioleiomyomatosis 1110
9.36 Lymphoma (general) 1111
9.37 Mast Cell Leukemia 1114
9.38 Mastocytosis 1115
9.39 Melanoma 1116
9.40 Mesothelioma 1121
9.41 Myelodysplastic Syndrome 1123
9.42 Myeloma 1126
9.43 Nasopharyngeal Cancer 1130
9.44 Neuroblastoma 1131
9.45 Neuroendocrine Cancer (general) 1132
9.46 Neuroendocrine Cancer (pancreatic) 1133
9.47 Neurofibromatosis 1135
9.48 Non-Hodgkin’s Lymphoma 1136
9.49 Non-Small Cell Lung Cancer 1139
9.50 Oesophageal Cancer 1148
9.51 Oral Cancer 1151
9.52 Osteo Sarcoma 1152
9.53 Ovarian Cancer 1153
9.54 Pancreatic Cancer 1159
9.55 Peritoneal Cancer 1165
9.56 Prostate Cancer 1167
9.57 Renal Cancer 1173
9.58 Rhabdomyo Sarcoma 1179
9.59 Sarcoma (general) 1180
9.60 Small Cell Lung Cancer 1183
9.61 Soft Tissue Sarcoma 1186
9.62 Solid Tumor 1188
9.63 Squamous Cell Cancer 1196
9.64 Synovial Sarcoma 1197
9.65 T-cell Lymphoma 1198
9.66 Testicular Cancer 1199
9.67 Thymoma Cancer 1200
9.68 Thyroid Cancer 1201
9.69 Unspecified Cancer Indication 1206
9.70 Waldenstrom’s hypergammaglobulinemia 1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator 1224
10.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 1229
10.2 Company Facts and Ranking 1231
10.3 Competitive Fall-Out Assessment 1238
10.4 4SC 1241
10.5 AB Science 1247
10.6 Abbott 1252
10.7 Abiogen 1264
10.8 Acceleron Pharma 1270
10.9 ACT Biotech 1276
10.10 Advenchen 1281
10.11 AEgera 1287
10.12 AEterna Zentaris 1291
10.13 Aida Pharmaceuticals 1298
10.14 Alethia Biotherapeutics 1302
10.15 Allist Pharmaceuticals 1307
10.16 Allostera 1313
10.17 AlphaVax 1318
10.18 Ambit Biosciences 1324
10.19 Amgen 1337
10.20 Amphora 1361
10.21 Ansaris 1377
10.22 Apogee Biotechnology 1381
10.23 Ariad 1385
10.24 Arno Therapeutics 1403
10.25 ArQule 1408
10.26 Array BioPharma 1420
10.27 Astellas 1437
10.28 Astex Pharmaceuticals 1455
10.29 AstraZeneca 1475
10.30 Avila Therapeutics 1508
10.31 Bavarian Nordic 1519
10.32 Bayer 1525
10.33 Benitec 1542
10.34 Berkeley Lab 1548
10.35 Bio-Path Holdings 1552
10.36 BioAxone 1557
10.37 Bionovo 1561
10.38 Biotecnol 1569
10.39 Biotica Technology 1575
10.40 Boehringer Ingelheim 1583
10.41 Bristol-Myers Squibb 1596
10.42 BTG 1621
10.43 Callisto Pharmaceuticals 1628
10.44 Cambrex 1632
10.45 CanBas 1636
10.46 Cancer Research Technology 1641
10.47 Catalyst Biosciences 1654
10.48 Celgene 1661
10.49 Cell Therapeutics 1672
10.50 CellCeutix 1676
10.51 Celleron 1680
10.52 Cephalon 1686
10.53 CerRx 1696
10.54 Chroma Therapeutics 1701
10.55 Circadian Technologies 1708
10.56 Cleveland BioLabs 1713
10.57 Clinical Data 1719
10.58 CompleGen 1724
10.59 Compugen 1730
10.60 CoNCERT Pharmaceuticals 1737
10.61 Curis 1745
10.62 Cyclacel 1753
10.63 Cylene Pharmaceuticals 1763
10.64 Cytokine PharmaSciences 1769
10.65 Cytopia 1774
10.66 Daiichi Sankyo 1779
10.67 Dainippon Sumitomo Pharma 1785
10.68 Debiopharm 1790
10.69 Deciphera Pharmaceuticals 1794
10.70 DeveloGen 1808
10.71 DiaMedica 1815
10.72 Dyax 1819
10.73 Eisai 1823
10.74 Elara Pharmaceuticals 1832
10.75 Eli Lilly 1838
10.76 Enkam Pharmaceuticals 1862
10.77 EntreMed 1867
10.78 Enzon 1873
10.79 Erimos 1879
10.80 Exelixis 1884
10.81 Galapagos 1912
10.82 Galena Biopharma 1917
10.83 Generex 1924
10.84 Gilead Sciences 1930
10.85 GlaxoSmithKline 1936
10.86 GlycoGenesys 1962
10.87 GPC Biotech 1967
10.88 Hanmi 1974
10.89 Hoffmann-La Roche 1988
10.90 Hutchison China MediTech 2016
10.91 Hypha Discovery 2024
10.92 Idera Pharmaceuticals 2032
10.93 ImClone Systems 2036
10.94 ImmunoFrontier 2042
10.95 Incozen Therapeutics 2048
10.96 Incyte Corporation 2054
10.97 Inhibiton Therapeutics 2062
10.98 Inovio 2066
10.99 Insmed 2072
10.100 Insys Therapeutics 2078
10.101 Intellikine 2084
10.102 Isis Pharmaceuticals 2094
10.103 ISU ABXIS 2099
10.104 Jina Pharmaceuticals 2106
10.105 Johnson & Johnson 2110
10.106 Kadmon 2121
10.107 KAI Pharmaceuticals 2126
10.108 KaloBios 2131
10.109 Kalypsys 2136
10.110 Karus Therapeutics 2141
10.111 Keryx Biopharmaceuticals 2145
10.112 Kiadis 2152
10.113 Kinex 2159
10.114 Kirin Pharma 2164
10.115 KuDOS 2172
10.116 Kyowa Hakko Kirin 2177
10.117 Leo 2187
10.118 Lexicon Pharmaceuticals 2192
10.119 Ligand 2196
10.120 Marina Biotech 2201
10.121 MaxoCore Pharmaceuticals 2206
10.122 Meda 2210
10.123 Medisyn Technologies 2217
10.124 Merck & Co 2224
10.125 Merck KGaA 2243
10.126 Merrimack 2249
10.127 MethylGene 2253
10.128 Micromet 2259
10.129 Mitsubishi Tanabe Pharma 2265
10.130 Molecular LogiX 2274
10.131 Myrexis 2279
10.132 Nano Terra 2283
10.133 Nerviano Medical Sciences 2287
10.134 NexusPharma 2301
10.135 NicOx 2305
10.136 Nidus Laboratories 2309
10.137 NIH 2315
10.138 Nippon Shinyaku 2320
10.139 Non-industrial Sources 2325
10.140 NovaLead 2329
10.141 Novartis 2336
10.142 Novogen 2375
10.143 Oncalis 2385
10.144 Onconova 2391
10.145 OncoTherapy Science 2402
10.146 Oncothyreon 2408
10.147 OSI Pharmaceuticals 2418
10.148 Pathway Therapeutics 2427
10.149 Peregrine Pharmaceuticals 2436
10.150 Pfizer 2443
10.151 Pharmacyclics 2496
10.152 PharmaGap 2501
10.153 PharmaMar 2507
10.154 Pharmexa 2514
10.155 Phoenix Biotechnology 2521
10.156 PHusis Therapeutics 2525
10.157 Pieris 2531
10.158 Piramal 2538
10.159 PIramed 2544
10.160 Portola Pharmaceuticals 2551
10.161 Proacta 2557
10.162 Progenics Pharmaceuticals 2562
10.163 Provid 2566
10.164 QLT 2570
10.165 Quantum Pharmaceuticals 2577
10.166 Ras Therapeutics 2584
10.167 Reata Pharmaceuticals 2588
10.168 Receptor BioLogix 2594
10.169 Rexahn 2598
10.170 Rigel 2610
10.171 Samtheo Biopharma 2620
10.172 Sanofi 2627
10.173 Sareum 2636
10.174 SBI Biotech 2648
10.175 SBIO 2653
10.176 Scancell 2663
10.177 Schering-Plough 2668
10.178 Selvita 2675
10.179 Semafore Pharmaceuticals 2681
10.180 Sentinel Oncology 2691
10.181 SGX Pharmaceuticals 2697
10.182 Silence Therapeutics 2702
10.183 Sunesis 2707
10.184 Supratek Pharma 2717
10.185 Swedish Orphan Biovitrum 2722
10.186 Switch Pharma 2727
10.187 Symphogen 2734
10.188 Takeda 2738
10.189 Tamir Biotechnology 2757
10.190 Targa Therapeutics 2761
10.191 TargeGen 2767
10.192 TauTaTis 2772
10.193 TCD Pharma 2776
10.194 Tekmira Pharmaceuticals 2780
10.195 Telik 2786
10.196 Teva 2800
10.197 Thallion Pharmaceuticals 2810
10.198 Theryte 2816
10.199 Tigris Pharmaceuticals 2821
10.200 ToolGen 2826
10.201 TopoTarget 2830
10.202 Tragara Pharmaceuticals 2838
10.203 TransTech Pharma 2842
10.204 UCB 2847
10.205 VasGene Therapeutics 2855
10.206 Velacor Therapeutics 2859
10.207 Vernalis 2865
10.208 Vertex Pharmaceuticals 2870
10.209 VioQuest 2880
10.210 ViroMed 2887
10.211 Wyeth 2893
10.212 Xcovery 2901
10.213 Xencor 2920
10.214 YM BioSciences 2927
10.215 Zenyaku Kogyo 2933
11 Disclaimer 2940

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Protein Kinase Drugs in Oncology 442
Figure 2: The Drug-Target Competitive Landscape of Protein Kinase Drugs in Oncology - Super Cluster 444
Figure 3: The Drug-Target Competitive Landscape Protein Kinase Drugs in Oncology - Smaller Clusters 445
Figure 4: Head-to-Head Targeting Competitive Landscape of Protein Kinase Drugs in Oncology 1 (2) 446
Figure 5: Head-to-Head Targeting Competitive Landscape of Protein Kinase Drugs in Oncology 2 (2) 447
Figure 6: Distribution of Compound Strategies among Protein Kinase Cancer Drugs 1006
Figure 7: Primary Sub-cellular Localization of Drug Targets 1007
Figure 8: Number of Companies per Ranking Level 1233

4.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Protein Kinase Drug Pipeline in Oncology by Stage of Development 38
Table 3: Head to Head Target Competition among Protein Kinase Drugs in Oncology 38
Table 4: Overview of Drug Target Strategy Themes 43
Table 5: Terminally Ceased Targets of Protein Kinase Drugs in Oncology 44
Table 6: Official Gene Name to Target Profle 45
Table 7: Targets of Protein Kinase Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 430
Table 8: Identity of Drug Targets with Available Biological Structures 435
Table 9: Number of Target-Target Interactions among Targets of Protein Kinase Drugs in Oncology 440
Table 10: Available Protein Expression Profiles of Protein Kinase Drug Targets in Oncology 448
Table 11: Pathway Summary 453
Table 12: Drug Targets without any Identified Assigned Pathways 453
Table 13: Pathway Profiles According to BioCarta of Protein Kinase Drug Targets in Oncology 455
Table 14: Pathway Profiles According to KEGG of Protein Kinase Drug Targets in Oncology 478
Table 15: Pathway Profiles According to NetPath of Protein Kinase Drug Targets in Oncology 506
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 517
Table 17: Top Competitive Target Strategies of Protein Kinase Drugs in Oncology 518
Table 18: New and Unique Target Strategies of Pre-registration to Marketed Protein Kinase Drugs in Oncology 520
Table 19: The Competition Through Close Mechanistic Approximation Between Protein Kinase Drugs in Oncology in Pre-registration to Marketed 521
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Protein Kinase Drugs in Oncology 522
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Protein Kinase Drugs in Oncology 524
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Protein Kinase Drugs in Oncology 526
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Protein Kinase Drugs in Oncology 531
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Protein Kinase Drugs in Oncology 536
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Protein Kinase Drugs in Oncology 543
Table 26: New and Unique Target Strategies in Preclinical Development of Protein Kinase Drugs in Oncology 550
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Protein Kinase Drugs in Oncology 558
Table 28: Target Strategies of No Data, Suspended and Terminated Protein Kinase Drugs in Oncology 566
Table 29: Connecting Target Strategy with Its Profile Identification Number 573
Table 30: The Competition Through Close Mechanistic Approximation Among Protein Kinase Drugs in Oncology 925
Table 31: Overview of Compound Strategy Competition Among Protein Kinase Cancer Drugs 947
Table 32: Overview of the Competitive Landscape of Small Molecule Based Protein Kinase Drugs in Oncology 949
Table 33: Competitive Comparison of Target Strategies of Small Molecule Protein Kinase Cancer Drugs 950
Table 34: Pursued Target Strategies of Small Molecule Drugs Based Protein Kinase Cancer Drugs 968
Table 35: Overview of the Competitive Landscape of Peptide Based Protein Kinase Drugs in Oncology 988
Table 36: Competitive Comparison of Target Strategies of Peptide Based Protein Kinase Cancer Drugs 989
Table 37: Pursued Target Strategies of Peptide Based Protein Kinase Cancer Drugs 989
Table 38: Overview of the Competitive Landscape of Protein Based Protein Kinase Drugs in Oncology 991
Table 39: Competitive Comparison of Target Strategies of Protein Based Protein Kinase Cancer Drugs 992
Table 40: Pursued Target Strategies of Protein Based Protein Kinase Cancer Drugs 992
Table 41: Overview of the Competitive Landscape of Antibody Based Protein Kinase Drugs in Oncology 993
Table 42: Competitive Comparison of Target Strategies of Antibody Based Protein Kinase Cancer Drugs 994
Table 43: Pursued Target Strategies of Antibody Based Protein Kinase Cancer Drugs 995
Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Protein Kinase Drugs in Oncology 998
Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Protein Kinase Cancer Drugs 999
Table 46: Pursued Target Strategies of Nucleic Acid Based Protein Kinase Cancer Drugs 999
Table 47: Potential Forms of Cell Therapy 1000
Table 48: Vectors in Gene Therapy 1001
Table 49: Overview of the Competitive Landscape of Cell Therapy Based Protein Kinase Drugs in Oncology 1001
Table 50: Pursued Target Strategies of Cell Therapy Based Pancreatic Cancer Drugs 1002
Table 51: Overview of the Competitive Landscape of Gene Therapy Based Protein Kinase Drugs in Oncology 1002
Table 52: Competitive Comparison of Target Strategies of Gene Therapy Based Protein Kinase Cancer Drugs 1003
Table 53: Pursued Target Strategies of Gene Therapy Based Protein Kinase Cancer Drugs 1003
Table 54:Overview of the Competitive Landscape of Reformulated Protein Kinase Drugs on Oncology 1004
Table 55: Pursued Target Strategies of Reformulated Protein Kinase Cancer Drugs 1005
Table 56: Compound Strategies based on Sub-Cellular Localization of Protein Kinase Cancer Drug Targets 1007
Table 57 Competitive Summary by Cancer Indication of Protein Kinase Drugs 1015
Table 58: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Acute Lymphocytic Leukemia 1017
Table 59: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs 1019
Table 60: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Acute Myelogenous Leukemia 1020
Table 61: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 1023
Table 62: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Adrenal Cancer 1025
Table 63: The Competition through Close Mechanistic Approximation between Adrenal Cancer Drugs 1025
Table 64: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of B-cell Lymphoma 1026
Table 65: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs 1027
Table 66: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Basal Cell Cancer 1028
Table 67: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Biliary Cancer 1029
Table 68: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Bladder Cancer 1030
Table 69: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 1031
Table 70: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Bone Cancer 1033
Table 71: The Competition through Close Mechanistic Approximation between Bone Cancer Drugs 1033
Table 72: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Brain Cancer 1034
Table 73: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 1036
Table 74: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Breast Cancer 1039
Table 75: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 1043
Table 76: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Cancer (general) 1049
Table 77: The Competition through Close Mechanistic Approximation between Cancer (general) Drugs 1050
Table 78: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Carcinoid 1051
Table 79: The Competition through Close Mechanistic Approximation between Carcinoid Drugs 1052
Table 80: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Cervical Cancer 1053
Table 81: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs 1054
Table 82: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Cervical Dysplasia 1055
Table 83: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Chronic Lymphocytic Leukemia 1056
Table 84: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs 1060
Table 85: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Chronic Myelogenous Leukemia 1061
Table 86: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs 1063
Table 87: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Chronic Myelomonocytic Leukemia 1065
Table 88: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of CNS Cancer 1065
Table 89: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Colorectal Cancer 1066
Table 90: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 1070
Table 91: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Cowden syndrome 1074
Table 92: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Endometrial Cancer 1075
Table 93: The Competition through Close Mechanistic Approximation between Endometrial Cancer Drugs 1076
Table 94: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Fallopian Tube Cancer 1078
Table 95: The Competition through Close Mechanistic Approximation between Fallopian Tube Cancer Drugs 1079
Table 96: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Fibro Sarcoma 1080
Table 97: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Cancer (general) 1081
Table 98: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 1083
Table 99: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Stomach Cancer 1084
Table 100: The Competition through Close Mechanistic Approximation between Cancer Drugs 1086
Table 101: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Stromal Cancer 1088
Table 102: The Competition through Close Mechanistic Approximation between Gastrointestinal Stromal Cancer Drugs 1089
Table 103: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Head and Neck Cancer 1091
Table 104: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 1093
Table 105: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Hematological Cancer (general) 1096
Table 106: The Competition through Close Mechanistic Approximation between Hematological Cancer (general) Drugs 1098
Table 107: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Hodgkin’s Lymphoma 1099
Table 108: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Leiomyo Sarcoma 1100
Table 109: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Leukemia (general) 1101
Table 110: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Lipo Sarcoma 1102
Table 111: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Liver Cancer 1103
Table 112: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 1105
Table 113: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Lung Cancer (general) 1108
Table 114: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs 1109
Table 115: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Lymphangioleiomyomatosis 1110
Table 116: The Competition through Close Mechanistic Approximation between Lymphangioleiomyomatosis Drugs 1110
Table 117: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Lymphoma (general) 1111
Table 118: The Competition through Close Mechanistic Approximation between Lymphoma (general) Drugs 1112
Table 119: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Mast Cell Leukemia 1114
Table 120: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Mastocytosis 1115
Table 121: The Competition through Close Mechanistic Approximation between Mastocytosis Drugs 1115
Table 122: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Melanoma 1116
Table 123: The Competition through Close Mechanistic Approximation between Melanoma Drugs 1119
Table 124: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Mesothelioma 1121
Table 125: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs 1122
Table 126: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Myelodysplastic Syndrome 1123
Table 127: The Competition through Close Mechanistic Approximation between Myelodysplastic Syndrome Drugs 1125
Table 128: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Myeloma 1126
Table 129: The Competition through Close Mechanistic Approximation between Myeloma Drugs 1128
Table 130: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Nasopharyngeal Cancer 1130
Table 131: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Neuroblastoma 1131
Table 132: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Neuroendocrine Cancer (general) 1132
Table 133: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Neuroendocrine Cancer (pancreatic) 1133
Table 134: The Competition through Close Mechanistic Approximation between Neuroendocrine Cancer (pancreatic) Drugs 1133
Table 135: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Neurofibromatosis 1135
Table 136: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of non-Hodgkin’s Lymphoma 1136
Table 137: The Competition through Close Mechanistic Approximation between Non-Hodgkin’s Lymphoma Drugs 1138
Table 138: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Non-Small Cell Lung Cancer 1139
Table 139: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 1143
Table 140: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Oesophageal Cancer 1148
Table 141: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs 1149
Table 142: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Oral Cancer 1151
Table 143: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Osteo Sarcoma 1152
Table 144: The Competition through Close Mechanistic Approximation between Osteo Sarcoma Drugs 1152
Table 145: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Ovarian Cancer 1153
Table 146: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 1156
Table 147: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Pancreatic Cancer 1159
Table 148: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 1163
Table 149: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Peritoneal Cancer 1165
Table 150: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs 1166
Table 151: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Prostate Cancer 1167
Table 152: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 1170
Table 153: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Renal Cancer 1173
Table 154: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 1176
Table 155: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Rhabdomyo Sarcoma 1179
Table 156: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Sarcoma (general) 1180
Table 157: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs 1182
Table 158: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Small Cell Lung Cancer 1183
Table 159: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 1184
Table 160: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Soft Tissue Sarcoma 1186
Table 161: The Competition through Close Mechanistic Approximation between Soft Tissue Sarcoma Drugs 1187
Table 162: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Solid Tumor 1188
Table 163: The Competition through Close Mechanistic Approximation between Solid Tumor Drugs 1192
Table 164: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Squamous Cell Cancer 1196
Table 165: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Synovial Sarcoma 1197
Table 166: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of T-cell Lymphoma 1198
Table 167: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Testicular Cancer 1199
Table 168: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Thymoma Cancer 1200
Table 169: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Thyroid Cancer 1201
Table 170: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs 1204
Table 171: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Unspecified Cancer Indication 1206
Table 172: The Competition through Close Mechanistic Approximation between Unspecified Cancer Type Drugs 1214
Table 173: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Waldenstrom’s hypergammaglobulinemia 1223
Table 174: Competitive Summary by Investigator of Protein Kinase Drug Development 1224
Table 175: Summary Table of Corporate Changes in the Competitive Landscape of Protein Kinase Drug Development in Oncology 1229
Table 176: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters 1232
Table 177: Example of a Competitive Fall-Out Table (Targeting KDR/Modified) 1238
Table 178: 4SC’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1243
Table 179: AB Science’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1249
Table 180: Abbott’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1255
Table 181: Abiogen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1266
Table 182: Acceleron Pharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1272
Table 183: ACT Biotech’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1278
Table 184: Advenchen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1283
Table 185: AEgera’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1288
Table 186: AEterna Zentaris’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1293
Table 187: Aida Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1299
Table 188: Alethia Biotherapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1304
Table 189: Allist Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1309
Table 190: Allostera’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1315
Table 191: AlphaVax’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1320
Table 192: Ambit Biosciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1328
Table 193: Amgen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1343
Table 194: Amphora’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1366
Table 195: Ansaris’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1378
Table 196: Apogee Biotechnology’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1382
Table 197: Ariad’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1390
Table 198: Arno Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1405
Table 199: ArQule’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1412
Table 200: Array BioPharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1425
Table 201: Astellas’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1442
Table 202: Astex Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1460
Table 203: AstraZeneca’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1482
Table 204: Avila Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1512
Table 205: Bavarian Nordic’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1521
Table 206: Bayer’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1530
Table 207: Benitec’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1544
Table 208: Berkeley Lab’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1549
Table 209: Bio-Path Holdings’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1554
Table 210: BioAxone’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1558
Table 211: Bionovo’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1564
Table 212: Biotecnol’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1571
Table 213: Biotica Technology’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1578
Table 214: Boehringer Ingelheim’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1587
Table 215: Bristol-Myers Squibb’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1603
Table 216: BTG’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1623
Table 217: Callisto Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1629
Table 218: Cambrex’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1633
Table 219: CanBas’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1638
Table 220: Cancer Research Technology’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1645
Table 221: Catalyst Biosciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1656
Table 222: Celgene’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1664
Table 223: Cell Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1673
Table 224: CellCeutix’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1677
Table 225: Celleron’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1682
Table 226: Cephalon’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1690
Table 227: CerRx’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1698
Table 228: Chroma Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1704
Table 229: Circadian Technologies’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1710
Table 230: Cleveland BioLabs’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1715
Table 231: Clinical Data’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1721
Table 232: CompleGen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1726
Table 233: Compugen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1733
Table 234: CoNCERT Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1740
Table 235: Curis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1748
Table 236: Cyclacel’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1756
Table 237: Cylene Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1765
Table 238: Cytokine PharmaSciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1771
Table 239: Cytopia’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1776
Table 240: Daiichi Sankyo’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1781
Table 241: Dainippon Sumitomo Pharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1787
Table 242: Debiopharm’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1791
Table 243: Deciphera Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1798
Table 244: DeveloGen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1811
Table 245: DiaMedica’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1816
Table 246: Dyax’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1820
Table 247: Eisai’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1826
Table 248: Elara Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1834
Table 249: Eli Lilly’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1844
Table 250: Enkam Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1864
Table 251: EntreMed’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1869
Table 252: Enzon’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1875
Table 253: Erimos’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1881
Table 254: Exelixis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1891
Table 255: Galapagos’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1914
Table 256: Galena Biopharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1920
Table 257: Generex’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1926
Table 258: Gilead Sciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1932
Table 259: GlaxoSmithKline’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1942
Table 260: GlycoGenesys’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1964
Table 261: GPC Biotech’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1969
Table 262: Hanmi’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1978
Table 263: Hoffmann-La Roche’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 1996
Table 264: Hutchison China MediTech’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2018
Table 265: Hypha Discovery’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2027
Table 266: Idera Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2033
Table 267: ImClone Systems’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2038
Table 268: ImmunoFrontier’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2044
Table 269: Incozen Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2050
Table 270: Incyte Corporation’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2057
Table 271: Inhibiton Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2063
Table 272: Inovio’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2068
Table 273: Insmed’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2074
Table 274: Insys Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2080
Table 275: Intellikine’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2087
Table 276: Isis Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2096
Table 277: ISU ABXIS’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2101
Table 278: Jina Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2107
Table 279: Johnson & Johnson’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2114
Table 280: Kadmon’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2123
Table 281: KAI Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2128
Table 282: KaloBios’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2133
Table 283: Kalypsys’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2138
Table 284: Karus Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2142
Table 285: Keryx Biopharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2148
Table 286: Kiadis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2155
Table 287: Kinex’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2161
Table 288: Kirin Pharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2167
Table 289: KuDOS’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2174
Table 290: Kyowa Hakko Kirin’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2180
Table 291: Leo’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2189
Table 292: Lexicon Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2193
Table 293: Ligand’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2198
Table 294: Marina Biotech’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2203
Table 295: MaxoCore Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2207
Table 296: Meda’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2212
Table 297: Medisyn Technologies’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2219
Table 298: Merck & Co’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2229
Table 299: Merck KGaA’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2245
Table 300: Merrimack’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2250
Table 301: MethylGene’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2255
Table 302: Micromet’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2261
Table 303: Mitsubishi Tanabe Pharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2268
Table 304: Molecular LogiX’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2276
Table 305: Myrexis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2280
Table 306: Nano Terra’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2284
Table 307: Nerviano Medical Sciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2291
Table 308: NexusPharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2302
Table 309: NicOx’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2306
Table 310: Nidus Laboratories’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2311
Table 311: NIH’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2317
Table 312: Nippon Shinyaku’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2322
Table 313: Non-industrial source’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2326
Table 314: NovaLead’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2332
Table 315: Novartis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2344
Table 316: Novogen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2379
Table 317: Oncalis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2387
Table 318: Onconova’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2394
Table 319: OncoTherapy Science’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2404
Table 320: Oncothyreon’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2412
Table 321: OSI Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2421
Table 322: Pathway Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2430
Table 323: Peregrine Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2438
Table 324: Pfizer’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2453
Table 325: Pharmacyclics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2498
Table 326: PharmaGap’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2503
Table 327: PharmaMar’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2510
Table 328: Pharmexa’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2516
Table 329: Phoenix Biotechnology’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2522
Table 330: PHusis Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2527
Table 331: Pieris’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2534
Table 332: Piramal’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2540
Table 333: PIramed’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2547
Table 334: Portola Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2553
Table 335: Proacta’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2559
Table 336: Progenics Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2563
Table 337: Provid’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2567
Table 338: QLT’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2573
Table 339: Quantum Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2579
Table 340: Ras Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2585
Table 341: Reata Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2590
Table 342: Receptor BioLogix’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2595
Table 343: Rexahn’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2601
Table 344: Rigel’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2613
Table 345: Samtheo Biopharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2623
Table 346: Sanofi’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2629
Table 347: Sareum’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2640
Table 348: SBI Biotech’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2650
Table 349: SBIO’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2656
Table 350: Scancell’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2665
Table 351: Schering-Plough’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2671
Table 352: Selvita’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2677
Table 353: Semafore Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2684
Table 354: Sentinel Oncology’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2693
Table 355: SGX Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2698
Table 356: Silence Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2704
Table 357: Sunesis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2710
Table 358: Supratek Pharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2719
Table 359: Swedish Orphan Biovitrum’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2724
Table 360: Switch Pharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2729
Table 361: Symphogen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2735
Table 362: Takeda’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2744
Table 363: Tamir Biotechnology’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2758
Table 364: Targa Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2763
Table 365: TargeGen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2769
Table 366: TauTaTis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2773
Table 367: TCD Pharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2777
Table 368: Tekmira Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2782
Table 369: Telik’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2791
Table 370: Teva’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2802
Table 371: Thallion Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2812
Table 372: Theryte’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2818
Table 373: Tigris Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2823
Table 374: ToolGen’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2827
Table 375: TopoTarget’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2833
Table 376: Tragara Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2839
Table 377: TransTech Pharma’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2844
Table 378: UCB’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2850
Table 379: VasGene Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2856
Table 380: Velacor Therapeutics’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2861
Table 381: Vernalis’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2867
Table 382: Vertex Pharmaceuticals’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2873
Table 383: VioQuest’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2883
Table 384: ViroMed’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2889
Table 385: Wyeth’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2896
Table 386: Xcovery’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2907
Table 387: Xencor’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2922
Table 388: YM BioSciences’ Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2929
Table 389: Zenyaku Kogyo’s Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 2935

This report includes 212 companies (Incl. Out of Business ones) plus their collaborators:
4SC
AB Science
Abbott
Abiogen
Acceleron Pharma
ACT Biotech
Advenchen
AEgera
AEterna Zentaris
Aida Pharmaceuticals
Alethia Biotherapeutics
Allist Pharmaceuticals
Allostera
AlphaVax
Ambit Biosciences
Amgen
Amphora
Ansaris
Apogee Biotechnology
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Pharmaceuticals
AstraZeneca
Avila Therapeutics
Bavarian Nordic
Bayer
Benitec
Berkeley Lab
BioAxone
Bionovo
Bio-Path Holdings
Biotecnol
Biotica Technology
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cambrex
CanBas
Cancer Research Technology
Catalyst Biosciences
Celgene
Cell Therapeutics
CellCeutix
Celleron
Cephalon
CerRx
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
Clinical Data
CompleGen
Compugen
CoNCERT Pharmaceuticals
Curis
Cyclacel
Cylene Pharmaceuticals
Cytokine PharmaSciences
Cytopia
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Deciphera Pharmaceuticals
DeveloGen
DiaMedica
Dyax
Eisai
Elara Pharmaceuticals
Eli Lilly
Enkam Pharmaceuticals
EntreMed
Enzon
Erimos
Exelixis
Galapagos
Galena Biopharma
Generex
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
GPC Biotech
Hanmi
Hoffmann-La Roche
Hutchison China MediTech
Hypha Discovery
Idera Pharmaceuticals
ImClone Systems
ImmunoFrontier
Incozen Therapeutics
Incyte Corporation
Inhibiton Therapeutics
Inovio
Insmed
Insys Therapeutics
Intellikine
Isis Pharmaceuticals
ISU ABXIS
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAI Pharmaceuticals
KaloBios
Kalypsys
Karus Therapeutics
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirin Pharma
KuDOS
Kyowa Hakko Kirin
Leo
Lexicon Pharmaceuticals
Ligand
Marina Biotech
MaxoCore Pharmaceuticals
Meda
Medisyn Technologies
Merck & Co
Merck KGaA
Merrimack
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Molecular LogiX
Myrexis
Nano Terra
Nerviano Medical Sciences
NexusPharma
NicOx
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
NovaLead
Novartis
Novogen
Oncalis
Onconova
OncoTherapy Science
Oncothyreon
OSI Pharmaceuticals
Pathway Therapeutics
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Phoenix Biotechnology
PHusis Therapeutics
Pieris
Piramal
PIramed
Portola Pharmaceuticals
Proacta
Progenics Pharmaceuticals
Provid
QLT
Quantum Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Rexahn
Rigel
Samtheo Biopharma
Sanofi
Sareum
SBI Biotech
SBIO
Scancell
Schering-Plough
Selvita
Semafore Pharmaceuticals
Sentinel Oncology
SGX Pharmaceuticals
Silence Therapeutics
Sunesis
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
Takeda
Tamir Biotechnology
Targa Therapeutics
TargeGen
TauTaTis
TCD Pharma
Tekmira Pharmaceuticals
Telik
Teva
Thallion Pharmaceuticals
Theryte
Tigris Pharmaceuticals
ToolGen
TopoTarget
Tragara Pharmaceuticals
TransTech Pharma
UCB
VasGene Therapeutics
Velacor Therapeutics
Vernalis
Vertex Pharmaceuticals
VioQuest
ViroMed
Wyeth
Xcovery
Xencor
YM BioSciences
Zenyaku Kogyo
This report includes 648 protein kinase drugs in cancer. From Ceased to Marketed. Some examples are:
AC-480
AE-37
AF-802
afatinib
alvocidib
AMG-386
Angiozyme
apatinib
AR-42
ARQ-197
AT-7519
AT-9283
axitinib
AZD-8055
AZD-8931
bafetinib
barasertib
bardoxolone methyl
BEZ-235
BGT-226
BI-811283
BIBF-1120
BMS-690514
BMS-754807
BMS-777607
bosutinib
brivanib alaninate
Cabozantinib
CAL-101
CBP-501
CC-223
cediranib
crizotinib
dacomitinib
danusertib
dasatinib
dinaciclib
dovitinib lactate
E-75
endoxifen
ENMD-2076
enzastaurin hydrochloride
erlotinib
everolimus
foretinib
fostamatinib disodium
gefitinib
GSK-2118436
IC-83
icrucumab
idronoxil
imatinib mesilate
INCB-028060
INSM-18
JI-101
KD032
KX2-391
lapatinib ditosylate
lenvatinib
lestaurtinib
linifanib
linsitinib
LY-2090314
masitinib
MGCD-265
midostaurin
MK-1775
MKC-1
MLN-8237
MM-111
motesanib diphosphate
MVA-BN Her-2 vaccine
neratinib
nilotinib
NPB-001-056
ON-01910
onartuzumab
OSI-027
OTS-102
P276-00
pazopanib hydrochloride
PD-0332991
pegdinetanib
perifosine
PHA-848125AC
plitidepsin
ponatinib
PX-866
quinacrine
quizartinib dihydrochloride
RAF-265
ramucirumab
regorafenib
ridaforolimus
rilotumumab
ruxolitinib
RX-0201-N
SCH-900776
seliciclib
sirolimus
sorafenib tosylate
ß-lapachone
SU-6668
sunitinib malate
talmapimod
tandutinib
telatinib
temsirolimus
terameprocol
tivozanib
triciribine phosphate
vandetanib
varlitinib
vemurafenib
volasertib
vosaroxin
XL-147
XL-281
XL-413
XL-647
XL-765

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others.
    To find out more about Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market
This report comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 152 companies, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and five subindications of lymphoma. Learn More


The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new protein kinase inhibitor drugs in oncology. Learn More

Other selected research from the 'Oncology' category:


Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others
This report represents a new and unique way of stratifying and analyzing the global protein kinase drug pipeline in oncology towards personalized medicine. Learn More


Target Atlas in Nasopharyngeal Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More